BPI Contributor

November 1, 2013

Miriam Monge (from Biopharm Services) revisits her March 2010 article (coauthored with Andrew Sinclair) in an audiocast with managing editor Maribel Rios. She reviewed the industry’s economic challenges at that time, which included costs associated with treatment, increasing market competition, and the rising demand for approved biosimilar products to offset healthcare costs. They wrote, “Many issues the biopharm sector faces appear to be the consequence of a maturing industry with structural impediments to its development brought about by regulation, political restrictions, and market structure.” In her audiocast, Monge reviews how those issues are affecting today’s industry. She discusses current issues and offers her projections on future challenges for the industry, including antibody–drug conjugates, cell therapies, personalized medicines, and the need process knowledge management.

You May Also Like